DOCSLIB.ORG

2020 Virtual Annual Meeting of the CMSC

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 Virtual Annual Meeting of the CMSC 2020 May 2020 • Volume 22, Supplement 2 Official Abstracts The Official Publication of the Consortium of Multiple Sclerosis Centers Downloaded from http://meridian.allenpress.com/ijmsc/article-pdf/22/s2/1/2539865/i1537-2073-22-s2-1.pdf by guest on 29 September 2021 2020 Virtual Annual Meeting of the CMSC Abstracts from the 34th Annual Meeting of the Consortium of Multiple Sclerosis Centers May – June 2020 Visit www.mscare.org to view archived meeting content. ijmsc.org EDITORIAL BOARD May 2020 • Vol. 22, Suppl. 2 Editor in Chief Francois Bethoux, MD Cleveland Clinic Cleveland, Ohio, USA Associate Editor Mary Alissa Willis, MD University of Mississippi Medical Center Jackson, Mississippi, USA Ex Officio 2020 Virtual Annual Meeting June Halper, MSN, ANP, FAAN Hackensack, New Jersey, USA Project Manager of the CMSC Charlene Belsole, CCRP Cleveland Clinic Cleveland, Ohio, USA Board Members he editorial team is pleased to present this supplement Downloaded from http://meridian.allenpress.com/ijmsc/article-pdf/22/s2/1/2539865/i1537-2073-22-s2-1.pdf by guest on 29 September 2021 Ted Brown, MD, MPH Evergreen Neuroscience Institute and Medical Center to the International Journal of MS Care (IJMSC) Kirkland, Washington, USA containing the abstracts from the 2020 Virtual Annual Susan Coote, PT, PhD University of Limerick T Meeting of the Consortium of Multiple Sclerosis Centers Limerick, Ireland Mary Filipi, PhD, APRN-C (CMSC). These abstracts include platform, poster, and Wahoo, Nebraska, USA Marcia Finlayson, PhD, OT Reg (Ont), OTR Whitaker Research Track presentations, as well as a few late- Queen’s University Kingston, Ontario, Canada breaking abstracts. In these unusual times, we all have had to Frederick W. Foley, PhD Yeshiva University modify many of our activities due to the COVID-19 pandemic, Bronx, New York, USA Holy Name Medical Center including the introduction of virtual scientific meetings. While Teaneck, New Jersey, USA Kathleen Fuchs, PhD the CMSC generously offers free registration to this meeting, University of Virginia Health System Charlottesville, Virginia, USA many health care providers may not have the time to attend the Eduard Gappmaier, PT, PhD University of Utah live online sessions. The print version of this supplement is being Salt Lake City, Utah, USA Christoph Heesen, MD distributed to members of the CMSC. The electronic version Institute of Neuroimmunology and Clinical MS Research will be available to all on the IJMSC website at ijmsc.org. University Medical Center Hamburg, Germany We would like to thank Sanofi Genzyme for their support, James Marriott, MD, FRCPC University of Manitoba which made this publication possible. Winnipeg, Manitoba, Canada While reading abstracts does not completely replace Lori Mayer, MSN, DNP(s), MSCN, CCRP MS Clinic of Central Texas Round Rock, Texas, USA in-person networking, our team hopes that this supplement will Sarah Morrow, MD, MSc, FRCPC attest to the fact that the desire to share innovation and research University of Western Ontario London Health Sciences Centre has not been extinguished by the pandemic. We hope that you London, Ontario, Canada Ahmed Z. Obeidat, MD, PhD and your loved ones are keeping safe in these challenging times. Medical College of Wisconsin Milwaukee, WI, USA Jacob J. Sosnoff, PhD University of Illinois at Urbana-Champaign —Francois Bethoux, MD Urbana, Illinois, USA Megan Weigel, DNP, ARNP-c Editor in Chief Baptist Medical Center Jacksonville Beach, Florida, USA Publishers Joseph J. D’Onofrio Frank M. Marino Delaware Media Group PO Box 937 Glen Rock, NJ 07452, USA [email protected] Managing Editor Anna Gillette Art Director James Ticchio International Journal of MS Care v CMSC Abstract Review Committee CO-CHAIRS Amy Perrin Ross, APN, MSN, CNRN, MSCN Loyola University of Chicago MS Clinic Chicago, IL [email protected] Carrie Hersh, DO, MSc Mellen Program for Multiple Sclerosis Lou Ruvo Center for Brain Health Downloaded from http://meridian.allenpress.com/ijmsc/article-pdf/22/s2/1/2539865/i1537-2073-22-s2-1.pdf by guest on 29 September 2021 Cleveland Clinic Nevada Las Vegas, NV [email protected] REVIEWERS Farren Briggs, PhD, ScM Rock Heyman, MD Cynthia Sullivan, PhD Case Western Reserve University University of Pittsburgh Medical Neuropsychology Associates of Fairfax, Cleveland, OH Center LLC [email protected] Pittsburgh, PA Fairfax, VA [email protected] [email protected] Dorothea Cassidy-Pfohl, RN, BS, MSCN Gloria Hou, MD Gloria von Geldern, MD Bala Cynwyd, PA University of Washington University of Washington Medical [email protected] Seattle, WA Center [email protected] Seattle, WA Kathleen Czuba, SLP [email protected] Loyola University Medical Center Sue Kushner, MS, PT Oak Brook Terrace, IL Slippery Rock University Jeff Wilken, PhD [email protected] Valencia, VA Neuropsychology Associates of Fairfax, [email protected] LLC Robert Fallis, MD, MSCS Fairfax, VA Ohio State University Beverly Layton, RN, BSN, CCRC, [email protected] Columbus, OH MSCN [email protected] Birmingham VA Medical Center Annette Wundes, MD Birmingham, AL Western MS Center at UWMC / Mary Kay Fink, RN, MSN, [email protected] MSRRTC ACNS-BC, MSCN Seattle, WA John L. Trotter Multiple Sclerosis Deborah Miller, PhD, LISW-S [email protected] Center Mellen Center for MS Treatment and St. Louis, MO Research [email protected] Cleveland, OH STAFF [email protected] Rachelle U. Ramirez Cindy Gackle, OTR/L, MSCS Multimedia Manager Minneapolis, MN Kelly Morton, PharmD Consortium of MS Centers [email protected] Loyola University of Chicago Hackensack, NJ MS Clinic Ajay Gupta, MD, MSCS [email protected] Chicago, IL Fort Wayne Neurological Center [email protected] Jennifer Pichardo Fort Wayne, IN Project Coordinator [email protected] Nancy Navarro, APN Consortium of MS Centers Suburban Physicians Colleen Harris, MN, NP, MSCN, MSCS Hackensack, NJ Aurora, IL University of Calgary MS Clinic [email protected] [email protected] Calgary, AB, Canada [email protected] International Journal of MS Care vi Abstract Titles (CRS02) Multiple Surgeries and Misdiagnosis Before Multiple Sclerosis PLATFORMS Diagnosis: A Case Report DISEASE ASSESSMENT AND MANAGEMENT (CRS03) Head Trauma as Onset for Multiple Sclerosis Diagnosis: A Case (DAM01) International Registry Tracking Pregnancy Outcomes in Women Report Treated with Dimethyl Fumarate (CRS04) Team Approach Yields Surprising Functional Progress and Quality-of- (DAM02) Menarche and Relapses in Girls with Pediatric Multiple Sclerosis Life Changes in a Challenging Case of Neuromyelitis Optica (DAM03) Complexity of Aging with Multiple Sclerosis: Graceful Concessions or (CRS05) Differential Diagnosis and Treatment of Tumefactive Demyelination in a Kicking and Screaming? Teenaged Girl (DAM04) Serum Glial Fibrillary Acidic Protein Is Elevated in a Subset of (CRS06) A Long-Standing Case of Recurrent Transverse Myelitis Due to Myelin Neuromyelitis Optica Patients and Associated with Increased Risk of Oligodendrocyte Glycoprotein (MOG)–IgG Antibody Mimicking Attacks Multiple Sclerosis (DAM05) Machine Learning Algorithms Applied to Visual Metrics to Classify (CRS07) Case Report of Severe Multiple Sclerosis Relapse Due to B-Cell Demyelinating Disease Diagnosis in Children Reconstitution Post Alemtuzumab (DAM06) Updated Recommendations for a Standardized Magnetic Resonance (CRS08) Demographics, Clinical Characteristics, and Outcomes of Myelin Imaging Protocol for Multiple Sclerosis Oligodendrocyte Glycoprotein (MOG) Antibody Disease Followed Up DISEASE-MODIFYING THERAPY at Washington University in St. Louis Downloaded from http://meridian.allenpress.com/ijmsc/article-pdf/22/s2/1/2539865/i1537-2073-22-s2-1.pdf by guest on 29 September 2021 (DMT01) Comparative Effectiveness of Switching from Natalizumab to a (CRS09) A Fatal Case of Alemtuzumab-Induced Immune Thrombocytopenic Moderate- Versus High-Efficacy Disease-Modifying Therapy in Clinical Purpura in a Patient with Relapsing Multiple Sclerosis Practice (CRS10) Colitis Associated with Teriflunomide (DMT02) Yearly Efficacy and Safety Outcomes Over 4 Years After Last (CRS11) Remarkable Recovery of Fulminant Multiple Sclerosis After Treatment Alemtuzumab Course in Pooled CARE-MS I and II Patients by Number Induction with Cyclophosphamide of Additional Courses Received Through Year 9 (CRS12) Neurofibromatosis Type 1 and Multiple Sclerosis in the Same Patient (DMT03) Efficacy and Safety of Ofatumumab Versus eriflunomideT in Patients (CRS13) Successful Use of Immunotherapy for Osmotic Demyelination with Relapsing Multiple Sclerosis: Phase 3 ASCLEPIOS I and II Trials Syndrome (DMT04) Treatment-Emergent Adverse Events Occurring Early in the Treatment DISEASE-MODIFYING THERAPY Course of Cladribine Tablets in Two Phase 3 Trials in Multiple Sclerosis (DXT01) Maintenance of Working Status and Work Productivity in Persons with PSYCHOSOCIAL: COGNITION Multiple Sclerosis Treated with Dimethyl Fumarate: A 5-Year Analysis (PSY01) A Mindfulness Group Intervention in Newly Diagnosed Persons with of the North American Research Committee on Multiple Sclerosis Multiple Sclerosis: A Pilot Study (NARCOMS) Registry (PSY02) Effects of Weekly Participation in a Wellness Program on Self-Reported (DXT02) Early Effect of Ofatumumab on B-Cell Counts and Magnetic Resonance Measures for People Living with Multiple Sclerosis: A 3-Year Analysis Imaging Activity in Relapsing Multiple Sclerosis Patients: Results from (PSY03) Examining Multilevel
Load more

Recommended publications
  • Ocrevus (Ocrelizumab) Policy Number: C11250-A
    Prior Authorization Criteria Ocrevus (ocrelizumab) Policy Number: C11250-A CRITERIA EFFECTIVE DATES: ORIGINAL EFFECTIVE DATE LAST REVIEWED DATE NEXT REVIEW DUE BY OR BEFORE 8/1/2017 2/17/2021 4/26/2022 LAST P&T J CODE TYPE OF CRITERIA APPROVAL/VERSION J2350-injection,ocrelizumab, Q2 2021 RxPA 1mg 20200428C11250-A PRODUCTS AFFECTED: Ocrevus (ocrelizumab) DRUG CLASS: Multiple Sclerosis Agents - Monoclonal Antibodies ROUTE OF ADMINISTRATION: Intravenous PLACE OF SERVICE: Specialty Pharmacy or Buy and Bill The recommendation is that medications in this policy will be for pharmacy benefit coverage and the IV infusion products administered in a place of service that is a non-hospital facility-based location (i.e., home infusion provider, provider’s office, free-standing ambulatory infusion center) AVAILABLE DOSAGE FORMS: Ocrevus SOLN 300MG/10ML FDA-APPROVED USES: Indicated for the treatment of: • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing- remitting disease, and active secondary progressive disease, in adults • Primary progressive MS, in adults COMPENDIAL APPROVED OFF-LABELED USES: None COVERAGE CRITERIA: INITIAL AUTHORIZATION DIAGNOSIS: Multiple Sclerosis REQUIRED MEDICAL INFORMATION: A. RELAPSING FORMS OF MULTIPLE SCLEROSIS: 1. Documentation of a definitive diagnosis of a relapsing form of multiple sclerosis as defined by the McDonald criteria (see Appendix), including: Relapsing- remitting multiple sclerosis [RRMS], secondary-progressive multiple sclerosis [SPMS] with relapses, and progressive- relapsing multiple sclerosis [PRMS] or First clinical episode with MRI features consistent with multiple sclerosis Molina Healthcare, Inc. confidential and proprietary © 2021 This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare.
    [Show full text]
  • SPECIALTY MEDICATION ADMINISTRATION – SITE of CARE REVIEW GUIDELINES Policy Number: PHARMACY 276.15 T2 Effective Date: September 1, 2017
    UnitedHealthcare® Oxford Clinical Policy SPECIALTY MEDICATION ADMINISTRATION – SITE OF CARE REVIEW GUIDELINES Policy Number: PHARMACY 276.15 T2 Effective Date: September 1, 2017 Table of Contents Page Related Policies INSTRUCTIONS FOR USE .......................................... 1 Actemra® (Tocilizumab) Injection for Intravenous CONDITIONS OF COVERAGE ...................................... 1 Infusion BENEFIT CONSIDERATIONS ...................................... 2 Entyvio® (Vedolizumab) COVERAGE RATIONALE ............................................. 2 Exondys 51™ (Eteplirsen) DEFINITIONS .......................................................... 3 Home Health Care DESCRIPTION OF SERVICES ...................................... 3 Infliximab (Remicade®, Inflectra™, Renflexis™) CLINICAL EVIDENCE ................................................. 3 ® REFERENCES ........................................................... 4 Orencia (Abatacept) Injection for Intravenous POLICY HISTORY/REVISION INFORMATION ................. 5 Infusion Radicava™ (Edaravone) Simponi Aria® (Golimumab) Injection for Intravenous Infusion Soliris® (Eculizumab) INSTRUCTIONS FOR USE This Clinical Policy provides assistance in interpreting Oxford benefit plans. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members. Oxford reserves the right, in its sole discretion, to modify its policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice. The term Oxford includes Oxford
    [Show full text]
  • New Biological Therapies: Introduction to the Basis of the Risk of Infection
    New biological therapies: introduction to the basis of the risk of infection Mario FERNÁNDEZ RUIZ, MD, PhD Unit of Infectious Diseases Hospital Universitario “12 de Octubre”, Madrid ESCMIDInstituto de Investigación eLibraryHospital “12 de Octubre” (i+12) © by author Transparency Declaration Over the last 24 months I have received honoraria for talks on behalf of • Astellas Pharma • Gillead Sciences • Roche • Sanofi • Qiagen Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Paul Ehrlich (1854-1915) • “side-chain” theory (1897) • receptor-ligand concept (1900) • “magic bullet” theory • foundation for specific chemotherapy (1906) • Nobel Prize in Physiology and Medicine (1908) (together with Metchnikoff) Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author 1981: B-1 antibody (tositumomab) anti-CD20 monoclonal antibody 1997: FDA approval of rituximab for the treatment of relapsed or refractory CD20-positive NHL 2001: FDA approval of imatinib for the treatment of chronic myelogenous leukemia Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Functional classification of targeted (biological) agents • Agents targeting soluble immune effector molecules • Agents targeting cell surface receptors
    [Show full text]
  • International Consensus Guidance for Management of Myasthenia Gravis 2020 Update
    VIEWS & REVIEWS OPEN ACCESS LEVEL OF RECOMMENDATION International Consensus Guidance for Management of Myasthenia Gravis 2020 Update Pushpa Narayanaswami, MBBS, DM, Donald B. Sanders, MD, Gil Wolfe, MD, Michael Benatar, MD, Correspondence Gabriel Cea, MD, Amelia Evoli, MD, Nils Erik Gilhus, MD, Isabel Illa, MD, Nancy L. Kuntz, MD, Janice Massey, MD, Dr. Narayanaswami Arthur Melms, MD, Hiroyuki Murai, MD, Michael Nicolle, MD, Jacqueline Palace, MD, David Richman, MD, and pnarayan@ Jan Verschuuren, MD bidmc.harvard.edu Neurology® 2021;96:114-122. doi:10.1212/WNL.0000000000011124 Abstract Objective To update the 2016 formal consensus-based guidance for the management of myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness method was used to develop consensus recommendations pertaining to 7 treatment topics. In February 2019, the international panel was reconvened with the addition of one member to represent South America. All previous recommendations were reviewed for currency, and new consensus recommendations were developed on topics that required inclusion or updates based on the recent literature. Up to 3 rounds of anonymous e-mail votes were used to reach consensus, with modifications to recommendations between rounds based on the panel input. A simple majority vote (80% of panel members voting “yes”) was used to approve minor changes in grammar and syntax to improve clarity. Results The previous recommendations for thymectomy were updated. New recommendations were developed for the use of rituximab, eculizumab, and methotrexate as well as for the following topics: early immunosuppression in ocular MG and MG associated with immune checkpoint inhibitor treatment.
    [Show full text]
  • Neuromyelitis Optica Spectrum Disorder
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-2596 Drug Class Review with New Drug Evaluation: Biologics for Autoimmune Disorders-Neuromyelitis Optica Spectrum Disorder Date of Review: April 2021 Date of Last Review: n/a Dates of Literature Search: 1/1/1996 – 1/20/2021 Generic Name: Brand Name (Manufacturer): Eculizumab Soliris® (Alexion Pharmaceuticals) Inebilizumab-cdon Uplizna™ (Viela Bio) Satralizumab-mwge Enspryng™ (Genentech/Roche) Dossiers Received: Yes Current Status of PDL Class: See Appendix 1. Purpose for Class Update: To define place in therapy for 3 immunosuppressive agents, eculizumab, inebilizumab-cdon, and satralizumab-mwge, recently approved by the Food and Drug Administration (FDA) for the treatment adults with neuromyelitis optica spectrum disorder (NMOSD). Research Questions: 1. What is the effectiveness of eculizumab, inebilizumab, and satralizumab in reducing time to relapse in adult patients with NMOSD who are anti-aquaporin-4 (AQP4) antibody positive? 2. What are the harms of eculizumab, inebilizumab-cdon and satralizumab in adults with NMOSD? 3. Is there comparative evidence that eculizumab, inebilizumab, and satralizumab differ in efficacy or harms for management of NMOSD? 4. Are there certain sub-populations (based on age, gender, ethnicity, comorbidities, disease duration or severity) in which eculizumab, inebilizumab, or satralizumab may be beneficial
    [Show full text]
  • Shands Confidentiality Agreement
    University of Florida College of Medicine – Jacksonville Visiting Student Application Checklist NAME: ROTATION: DATES: HOME SCHOOL: Do you need housing while rotating in Jacksonville? ______ YES ______ NO ***Housing is not guaranteed to visiting students, but we will make every effort to accommodate your request*** EMERGENCY CONTACT INFORMATION Name Phone Address ****Do NOT submit your application until all items have been completed**** Incomplete applications will not be considered – Submission Instructions on page 2 Students: Initial in each blank to certify each document has been completed and included in your application ________ Application for Extramural Course ________ Shands Confidentiality Agreement ________ Required Health Record ________ Parking Application* ________ Liability Confirmation Form ________ Copy of vehicle registration* ________ Background and Drug Screen Affidavit ________ CV/Resume ________ HIPAA Training Certificate ________ USMLE Step 1 Scores (MD/DO only) ________ UF Confidentiality Statement * If you plan to rent a vehicle, you may submit this document at check-in FOR OEA USE ONLY – STUDENTS: DO NOT WRITE BELOW THIS LINE Application Received Sent to Department Contract Obligations Insurance: SIP EX AI Dorm: No Yes / Invoice ________ Enter Applicant in NI ________ Application uploaded to NI ________ Computer access sent to student & coordinator NOTES UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE –JACKSONVILLE APPLICATION FOR EXTRAMURAL COURSE Mail Application to: Medical Student Administrator Office of Educational Affairs Kelsey Kyne (904) 244-5128 [email protected] c/o Student Administrator Medical Student Coordinator 653-1 W. 8th Street, Box L-15 Karen Sisco (904) 244-8233 [email protected] Jacksonville, FL 32209 Fax Numbers (904) 244-8997 OR (904) 244-4771 This form must be filled out completely – no substitute will be accepted – and must include the completed Required Health Record Section (page 2) before any rotation request will be considered.
    [Show full text]
  • On-Demand CME/CE Activities Available International Stroke
    7:00 AM 8:00 AM 9:00 AM 10:00 AM 11:00 AM 12:00 PM 1:00 PM 2:00 PM 3:00 PM 4:00 PM 5:00 PM 6:00 PM SCHEDULE-AT-A-GLANCE State-of-the-Science Stroke Nursing Symposium Pre-Conference Symposium I: Stroke in the Real World: Working Man Blues: Challenges in Inpatient Stroke Care Pre-Conference Symposium II (Student/Trainee/ TUES • FEB. 10 Early Career): Emerging Trends for Stroke Trials International Stroke Conference 2015 Symposia Symposia Targeting Spreading Door-to-needle or Depolarizations in Injured Call-to-needle Challenges Brain: Triggers, Modulators across Health Care Symposia Symposia and Causation Systems Problems with STAIRing Down the Barrel Interventions in Acute of a Loaded Research Gun: Cerebral Small Vessel Contralesional Stroke: 7 Little Things Disease in the Community: Hemisphere in Stroke How Useful Are the STAIR PLENARY SESSION I Criteria 15 Years Later? Prevalence, Causes and Recovery: Vascular and Cerebrovascular Vessel PROFESSOR-LED Clinical Relevance Neuronal Perspectives AHA’s CEO Welcome Wall Imaging: State of Improving Stroke Care for the Art Women POSTER TOUR Neuroinflammation and Childhood Stroke: AHA Presidential Cognitive Dysfunction in The Heart of the Matter Address Genetics and Stroke Moyamoaya Disease: SESSIONS Aneurysmal Subarachnoid Outcome Present and Future (60 MINS) Hemorrhage Oral Abstracts Thomas Willis Diagnosis of Stroke Lecture Oral Abstracts Reperfusion: The Latest, Emergency Care/Systems The Present, The Future REGULAR WED • FEB 11 Oral Abstracts Etiology Oral Abstracts I Late-Breaking Oral Abstracts
    [Show full text]
  • Statistical Analysis Plan
    Official Title: A Phase IIIb, Open-Label Study to Evaluate the Safety and Tolerability of Shorter Infusions of Ocrelizumab in Patients With Primary Progressive and Relapsing Multiple Sclerosis NCT Number: NCT03606460 Document Date: SAP Version 1: 26-June-2019 STATISTICAL ANALYSIS PLAN TITLE: A PHASE IIIB, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SHORTER INFUSIONS OF OCRELIZUMAB IN PATIENTS WITH PRIMARY PROGRESSIVE AND RELAPSING MULTIPLE SCLEROSIS PROTOCOL NUMBER: ML40638 STUDY DRUG: Ocrelizumab (RO4964913) VERSION NUMBER: 1 IND NUMBER: 100,593 EUDRACT NUMBER: Not applicable SPONSOR: Genentech, Inc. PLAN PREPARED BY: DATE FINAL: 26 June, 2019 STATISTICAL ANALYSIS PLAN APPROVAL Approved by Ph.D. on June 26, 2019 CONFIDENTIAL This is a Genentech, Inc. document that contains confidential information. Nothing herein is to be disclosed without written consent from Genentech, Inc. Ocrelizumab—Genentech, Inc. Statistical Analysis Plan ML40638 Clinical Study Report: Ocrelizumab — Genentech, Inc. CSR ML40638 370 TABLE OF CONTENTS 1. BACKGROUND ............................................................................................ 5 2. STUDY DESIGN ........................................................................................... 5 2.1 Protocol Synopsis .................................................................... 6 2.2 Outcome Measures ................................................................. 6 2.2.1 Primary Endpoint ..................................................................... 6 2.2.2 Secondary
    [Show full text]
  • The Ocrelizumab Pharmacy Service at the Leeds Teaching Hospitals NHS Trust (LTHT): Improving the Patient Experience
    The Ocrelizumab Pharmacy Service at the Leeds Teaching Hospitals NHS Trust (LTHT): Improving the Patient Experience Jeremy Robson & Sumrah Shaffiq, Leeds Teaching Hospitals NHS Trust Neurology Academy MS Advanced MasterClass 9.2 Background In 2018, the approval of Ocrevus (ocrelizumab) offered another treatment option for the management of relapsing remitting Multiple Sclerosis (RRMS)1, but the breakthrough decision came in 2019 upon its approval for early primary progressive MS (PPMS)2. The West Yorkshire MS Treatment Programme (WYMST) was set up to centralise a multi- district clinic and provides an effective model to ensure appropriate and equitable treatment for people with MS3. The WYMST has approximately 600 RRMS and approximately 100 PPMS from Leeds. Patients eligible for ocrelizumab are consented by the MS team and the prescribing is undertaken by independent pharmacist prescribers (IPPs). Ocrelizumab is administered on the LTHT day case unit, which is also used for the management of other neurology conditions. The IPPs contribute to the prescribing for these patients. Prescribing of ocrelizumab is undertaken on paper drug charts. At LTHT, the compounding of a majority of monoclonal antibodies (MAbs) (e.g. rituximab, alemtuzumab, infliximab, ocrelizumab) are overseen by the aseptics department. This is the default position to guarantee a sterile product and also mitigate the potential risk to staff members. This part of the service review involved challenging discussions between the IPPs, their aseptics colleagues and the MS team. The approval of ocrelizumab for RRMS and PPMS means a potential increase in prescribing, day case admissions and aseptics involvement in the manufacture of MAbs. A service review was warranted to establish if the current approach ensured the LTHT ocrelizumab service was efficient, safe and patient-centred.
    [Show full text]
  • Attachment: Extract from Clinical Evaluation Ocrelizumab
    AusPAR Attachment 2 Extract from the Clinical Evaluation Report for ocrelizumab Proprietary Product Name: Ocrevus Sponsor: Roche Products Pty Limited First round report: October 2016 Second round report: February 2017 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) · The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible for regulating medicines and medical devices. · The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website < https://www.tga.gov.au>. About the Extract from the Clinical Evaluation Report · This document provides a more detailed evaluation of the clinical findings, extracted from the Clinical Evaluation Report (CER) prepared by the TGA. This extract does not include sections from the CER regarding product documentation or post market activities. · The words (Information redacted), where they appear in this document, indicate that confidential information has been deleted. · For the most recent Product Information (PI), please refer to the TGA website < https://www.tga.gov.au/product-information-pi>.
    [Show full text]
  • Middle Level IM-MS and CIU Experiments for Improved Therapeutic Immunoglobulin Subclass Fingerprinting ACS Paragon Plus Environment Analytical Chemistry T
    Middle level IM-MS and CIU experiments for improved therapeutic immunoglobulin subclass fingerprinting ACS Paragon Plus Environment Analytical Chemistry T. Botzanowski, O. Hernandez-Alba, M. Malissard, E. Wagner-Rousset, E. Desligniere, O. Colas, F. Haeuw J., A. Beck, S. Cianferani To cite this version: T. Botzanowski, O. Hernandez-Alba, M. Malissard, E. Wagner-Rousset, E. Desligniere, et al.. Middle level IM-MS and CIU experiments for improved therapeutic immunoglobulin subclass fingerprinting ACS Paragon Plus Environment Analytical Chemistry. Analytical Chemistry, American Chemical Society, 2020, 92 (13), pp.8827-8835. 10.1021/acs.analchem.0c00293. hal-02960844 HAL Id: hal-02960844 https://hal.archives-ouvertes.fr/hal-02960844 Submitted on 8 Oct 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Analytical Chemistry This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.
    [Show full text]
  • Together for a Safe Campus
    ANNUAL SECURITY AND FIRE SAFETY REPORT • 2019 TOGETHER FOR A SAFE CAMPUS UF HEALTH JACKSONVILLE CAMPUS • WWW.HSCJ.UFL.EDU Together for a Safe Campus: UF Health Jacksonville he University of Florida Police Department, a State of Florida and Nationally and Internationally accredited T law enforcement agency, was established to provide protection and service to the university community. We are committed to the prevention of crime and the protection of life and property; the preservation of peace, order, and safety; the enforcement of all laws and ordinances; and the safeguarding of your constitutional guarantees. The University of Florida Police Department is staffed by highly trained officers and Police Service Technicians (PSTs) who utilize only the very latest tools in the fight against crime to be better prepared to keep the campus community as safe as possible. The University of Florida has an array of services in place to promote an environment that is as crime-free as possible. We encourage you to familiarize yourself with these services and take advantage of them to help make your educational and living experience at the University of Florida as enjoyable and crime-free as possible. I encourage you to contact our Community Services Division at (352) 392-1409 and visit the department’s web site on-line at http://www.police.ufl.edu for additional information on available programs and services. — Chief Linda J. Stump-Kurnick Contents he UF Health Jacksonville Security Department is the main security provider for the University of Florida 2 Safety and Security a Shared T Health Jacksonville Campus.
    [Show full text]